Entrada Therapeutics has been granted a patent for compositions and methods to treat Mitochondrial Neurogastrointestinal Encephalopathy Syndrome (MNGIE). The patent covers compounds with cell-penetrating and thymidine phosphorylase activity, involving a cyclic cell-penetrating peptide coupled to thymidine phosphorylase. GlobalData’s report on Entrada Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Entrada Therapeutics, Cyclosporin derivatives was a key innovation area identified from patents. Entrada Therapeutics's grant share as of May 2024 was 12%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of mitochondrial neurogastrointestinal encephalopathy syndrome using specific compounds
A recently granted patent (Publication Number: US11987821B2) discloses a compound with a specific structure according to Formula I-A, comprising a cyclic cell-penetrating peptide (cCPP) linked to thymidine phosphorylase (TP) with a defined amino acid sequence. The compound includes a linker (L) covalently bound to the side chain of an amino acid on the cCPP and the N-terminus of the TP, with L having various structural configurations as outlined in the claims.
Furthermore, the patent details additional features of the compound, such as the presence of specific structures (Formula II-A' or II-B'), the inclusion of alkylene, alkenylene, alkynylene, carbocyclyl, or heterocyclyl groups, and the option for a water-soluble polymer conjugated to the TP. The compound's composition may also involve hydrophobic aromatic amino acids, a polyethylene glycol (PEG) residue with a defined molecular weight range, and specific amino acid sequences for the TP and cCPP components. The claims further specify the arrangement of amino acids within the cCPP sequence, emphasizing the importance of consecutive arginine residues, hydrophobic aromatic amino acids, and alternating chirality amino acids.
To know more about GlobalData’s detailed insights on Entrada Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
